Targets › TPZM
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on TPZM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Teclison | Trans-arterial tirapazamine embolization (TATE) Hypoxia-activated prodrug embolized intra-arterially to deliver tirapazamine to liver tumo | TPZM | Phase 2 | Hepatocellular Carcinoma | Dec 2026 |
Hepatocellular Carcinoma (2)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.